OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $149.75 million. The enterprise value is $145.13 million.
| Market Cap | 149.75M |
| Enterprise Value | 145.13M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.84 million shares outstanding. The number of shares has increased by 3.84% in one year.
| Current Share Class | 18.84M |
| Shares Outstanding | 18.84M |
| Shares Change (YoY) | +3.84% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 15.12% |
| Owned by Institutions (%) | 60.44% |
| Float | 14.48M |
Valuation Ratios
The trailing PE ratio is 32.31 and the forward PE ratio is 8.46.
| PE Ratio | 32.31 |
| Forward PE | 8.46 |
| PS Ratio | 1.52 |
| Forward PS | 1.49 |
| PB Ratio | 1.14 |
| P/TBV Ratio | 6.96 |
| P/FCF Ratio | 8.16 |
| P/OCF Ratio | 8.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.33, with an EV/FCF ratio of 7.91.
| EV / Earnings | 31.54 |
| EV / Sales | 1.47 |
| EV / EBITDA | 9.33 |
| EV / EBIT | 12.88 |
| EV / FCF | 7.91 |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.15.
| Current Ratio | 5.58 |
| Quick Ratio | 5.27 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.23 |
| Debt / FCF | 1.06 |
| Interest Coverage | 2.41 |
Financial Efficiency
Return on equity (ROE) is 3.68% and return on invested capital (ROIC) is 5.91%.
| Return on Equity (ROE) | 3.68% |
| Return on Assets (ROA) | 4.22% |
| Return on Invested Capital (ROIC) | 5.91% |
| Return on Capital Employed (ROCE) | 7.29% |
| Weighted Average Cost of Capital (WACC) | 10.75% |
| Revenue Per Employee | $741,759 |
| Profits Per Employee | $34,594 |
| Employee Count | 133 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $2.15 million in taxes.
| Income Tax | 2.15M |
| Effective Tax Rate | 31.85% |
Stock Price Statistics
The stock price has decreased by -54.65% in the last 52 weeks. The beta is 1.05, so OptimizeRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -54.65% |
| 50-Day Moving Average | 6.65 |
| 200-Day Moving Average | 8.53 |
| Relative Strength Index (RSI) | 60.75 |
| Average Volume (20 Days) | 248,666 |
Short Selling Information
The latest short interest is 1.15 million, so 6.12% of the outstanding shares have been sold short.
| Short Interest | 1.15M |
| Short Previous Month | 1.36M |
| Short % of Shares Out | 6.12% |
| Short % of Float | 7.95% |
| Short Ratio (days to cover) | 4.47 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $98.65 million and earned $4.60 million in profits. Earnings per share was $0.25.
| Revenue | 98.65M |
| Gross Profit | 72.24M |
| Operating Income | 11.26M |
| Pretax Income | 6.75M |
| Net Income | 4.60M |
| EBITDA | 15.55M |
| EBIT | 11.26M |
| Earnings Per Share (EPS) | $0.25 |
Balance Sheet
The company has $24.10 million in cash and $19.48 million in debt, with a net cash position of $4.62 million or $0.25 per share.
| Cash & Cash Equivalents | 24.10M |
| Total Debt | 19.48M |
| Net Cash | 4.62M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 131.08M |
| Book Value Per Share | 6.96 |
| Working Capital | 44.44M |
Cash Flow
In the last 12 months, operating cash flow was $18.43 million and capital expenditures -$77,000, giving a free cash flow of $18.36 million.
| Operating Cash Flow | 18.43M |
| Capital Expenditures | -77,000 |
| Depreciation & Amortization | 4.29M |
| Net Borrowing | -10.31M |
| Free Cash Flow | 18.36M |
| FCF Per Share | $0.97 |
Margins
Gross margin is 73.22%, with operating and profit margins of 11.42% and 4.66%.
| Gross Margin | 73.22% |
| Operating Margin | 11.42% |
| Pretax Margin | 6.84% |
| Profit Margin | 4.66% |
| EBITDA Margin | 15.76% |
| EBIT Margin | 11.42% |
| FCF Margin | 18.61% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.84% |
| Shareholder Yield | -3.84% |
| Earnings Yield | 3.07% |
| FCF Yield | 12.26% |
Analyst Forecast
The average price target for OptimizeRx is $12.40, which is 55.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.40 |
| Price Target Difference | 55.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 4.46 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.46 |
| Piotroski F-Score | 7 |